Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: Role of topoisomerase I

Biochemical Pharmacology

Volumn 47, Issue 11, 1994, Pages 2105-2110

  Sørensen, Boe S ^a   Jensen, Peter B ^b   Sehested, Maxwell ^c   Jensen, Palle S ^a   Kjeldsen, Eigil ^a   Nielsen, Ole F ^a   Alsner, Jan ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b University of Copenhagen   (Denmark)

^c AMAGER HOSPITAL   (Denmark)

Author keywords

aclarubicin; antagonistic effect; camptothecin; topoisomerase I

Indexed keywords

ACLARUBICIN; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); INTERCALATING AGENT; RADIOISOTOPE;

ARTICLE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG ANTAGONISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ACLARUBICIN; CAMPTOTHECIN; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; HUMAN; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028223750     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(94)90087-6     Document Type: Article

References (46)

1. DNA topoisomerase poisons as antitumor drugs
2. DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogs
3. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I
4. Expression of human DNA topoisomerase I in yeast cells lacking DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin
5. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme DNA complex
6. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
7. Sequence dependent effect of camptothecin on human topoisomerase I DNA cleavage
8. DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy
9. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
10. DNA topoisomerase II as the primary target of the anti-tumor anthracyclines
11. Differential modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance
12. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidein human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
13. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence
14. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives
15. Inhibition of type II topoisomerase by fostriecin
16. Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage
17. Interactions between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
18. Principles and practice of DNA filter elution
19. 2 as a DNA fragmenting agent in the alkaline elution interstrand crosslinking and DNA-protein crosslinking assays
20. Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines
21. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung (SCCL)
22. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL)
23. Differential cytotoxicity of 19 anticancer agents in wild type and VP-16 resistant small cell lung cancer cell lines
24. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin
25. Stimulation of topoisomerase II mediated DNA cleavage at specific sequence elements by the 2-nitroimidazole Ro 15-0216
26. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
27. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
28. Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
29. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
30. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage
31. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II
32. Abrogation of etoposide-mediated cytotoxicity by cycloheximide
33. Inhibition of protein synthesis reduces the cytotoxicity of 4′ (9-acridinylamino)methanesulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line
34. Modulation of topoisomerase targeted drugs by minor-groove binding agents
35. Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses
36. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA
37. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome
38. A high affinity topoisomerase I binding sequence is clustered at DNAse I hypersensitive sites in Tetrahymena R- chromatin
39. Sites of topoisomerase I action on X. laevis ribosomal chromatin: transcriptionally active rDNA has an approximately 200 bp repeating structure
40. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerase I and II
41. Effects of minor groove binding drugs on camptothecininduced DNA lesions in L1210 nuclei
42. Distamycin inhibition of topoisomerase I-DNA interaction: a mechanistic analysis
43. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4′,6-diamine-2-phenylindole
44. DNA minor-groove binding agents interfere with topoisomerase II-mediated lesions induced by epipodophyllotoxin derivative VM26 and acridine derivative mAMSA in nuclei from L1210 cells
45. Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure-activity relationships of marcellomycin and its analogues as compared to adriamycin
46. Interactions between an anthracycline antibiotic and DNA: molecular structure of daunorubicin complexed to d(CpGpTpApCpG) at 1.2-Å resolution